---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-056553"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T17:41:57.583053+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Travere Therapeutics prices $200M public offering of common stock and pre-funded warrants

## Summary
- Offering of 8,275,000 shares at $21.00/share and 1,250,000 pre-funded warrants at $20.9999 each.
- Gross proceeds ~$200M; net proceeds ~$187.6M after underwriting discounts and expenses.
- Proceeds to support commercial launch of FILSPARI (sparsentan) for IgAN and potential FSGS launch.
- Underwriters granted 30-day option to purchase up to 1,428,750 additional shares.
- Closing expected March 3, 2023; Jefferies, J.P. Morgan, BofA Securities, SVB Securities as joint book-runners.

## SEC filing metadata
- accession: 0001193125-23-056553
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000119312523056553/0001193125-23-056553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000119312523056553/d442636d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-056553
- JSON: https://secwatch.observer/filing/0001193125-23-056553.json
- Plain text: https://secwatch.observer/filing/0001193125-23-056553.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.